Perioperative

Baxter Reports Fourth-Quarter and Full-Year 2023 Results

Retrieved on: 
Thursday, February 8, 2024
Medical Supplies, Health, Medical Devices, General Health, Pharmaceutical, Optical, Biotechnology, EPS, Task force, DNA, Nursing care plan, Piperacillin, Noise, Corporate social responsibility, FDA, Corporation, Medicine, UN, Dow Jones, EMR, Failure, Baxter International, Growth, Perioperative, TCFD, DJSI, Patient, Tazobactam, Centrella, Skin, Thrombin, Risk, Warburg Pincus, Acute liver failure, Galaxy, PD, NuVasive, Peritoneal dialysis, Risk management, Advent International, BPS, Sale, Eye, CST, Pharmaceutical industry

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2023, and provided its financial guidance for full-year and first-quarter 2024.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2023, and provided its financial guidance for full-year and first-quarter 2024.
  • For full-year 2023, net income attributable to Baxter on a U.S. GAAP basis totaled $2.66 billion, or $5.25 per diluted share.
  • In 2023, the company was named to the Dow Jones Sustainability Index (DJSI) North America, which has included Baxter each year since it launched in 2005.
  • For full-year 2024: Baxter expects sales growth of approximately 2% on both a reported and constant currency basis.

Allay Therapeutics Announces Development and Commercialization Agreement with Maruishi Pharmaceutical for Ultra-Sustained Pain Therapeutics in Japan

Retrieved on: 
Monday, December 18, 2023
Biotechnology, Surgery, Health, Pharmaceutical, Health Technology, Quality of life, Pain management, ATX, Perioperative, Pain, LLP, Therapy, Opioid, TKA, Patient, Cooley LLP

Allay Therapeutics, Inc. (Allay) today announced that they have entered into a license agreement with Maruishi Pharmaceutical Co., Ltd. (Maruishi), providing Maruishi with exclusive rights to develop and commercialize Allay’s lead investigational drug candidate, ATX101, and other ultra-sustained analgesic implantable drug candidates for acute pain in Japan.

Key Points: 
  • Allay Therapeutics, Inc. (Allay) today announced that they have entered into a license agreement with Maruishi Pharmaceutical Co., Ltd. (Maruishi), providing Maruishi with exclusive rights to develop and commercialize Allay’s lead investigational drug candidate, ATX101, and other ultra-sustained analgesic implantable drug candidates for acute pain in Japan.
  • Allay retains the right to develop and commercialize ATX101 in all territories outside of Japan.
  • "Maruishi is one of the leading specialty pharmaceutical companies in perioperative care and anesthetic settings, with strong development and commercial capabilities within the acute post-operative pain management arena,” said Adam Gridley, Chief Executive Officer of Allay.
  • "We’re especially excited to partner with Maruishi given their similar mission to improve quality of life and ease post-surgical recovery.

New Study Finds Significant Correlation Between Masimo ORi™ and Arterial Partial Pressure of Oxygen During One-Lung Ventilation

Retrieved on: 
Monday, December 11, 2023
Biotechnology, Surgery, Health, Pharmaceutical, Health Technology, Odds ratio, Samsung Medical Center, De novo, Blood, OLV, Sungkyunkwan University, Hypoxemia, Risk, MASI, Patient, Multimedia, Journal, FDA, Hyperoxia, Oxygen, Blood gas tension, Perioperative, Ori, Oxygen saturation (medicine), Receiver operating characteristic, Medical device, Medical imaging, Anesthesia, ROC

ORi is trended continuously with SpO2 as a unit-less index between 0.00 and 1.00 to extend the visibility of the patient oxygenation beyond SpO2 under supplemental oxygen.

Key Points: 
  • ORi is trended continuously with SpO2 as a unit-less index between 0.00 and 1.00 to extend the visibility of the patient oxygenation beyond SpO2 under supplemental oxygen.
  • During anesthesia, ORi was monitored using Masimo RD rainbow SET® Pulse CO-Oximetry sensors, and blood gas analysis was performed 15 minutes after OLV was initiated.
  • Of the 11 potential predictors for PaO2
  • The researchers concluded, “ORi values during one-lung ventilation were significantly correlated with PaO2 measured simultaneously.

Now Open, the Verstandig Pavilion at MedStar Georgetown University Hospital, Providing World-Class Care in a World-Class Facility

Retrieved on: 
Wednesday, December 13, 2023
Medicine, Anatomy, Risk, Surgeon, Brain, Patient, Multimedia, Intensive care medicine, MedStar Georgetown University Hospital, MedSTAR, IMRIS, Neurosurgery, Perioperative, MedStar Health, Electrode, Operating, Health, Hospital, Medical imaging, MD, Jesuits

WASHINGTON, Dec. 13, 2023 /PRNewswire/ -- MedStar Georgetown University Hospital and MedStar Health proudly announce the opening of the new Verstandig Pavilion, a transformative project for the region.

Key Points: 
  • WASHINGTON, Dec. 13, 2023 /PRNewswire/ -- MedStar Georgetown University Hospital and MedStar Health proudly announce the opening of the new Verstandig Pavilion, a transformative project for the region.
  • This facility enables MedStar Georgetown to continue providing world-class care now in a world-class facility unlike anywhere else in the metropolitan area.
  • "The Verstandig Pavilion is a transformational facility," said Mike Sachtleben, senior vice president and chief operating officer, Washington Region, MedStar Health and has been involved in the pavilion project from the very beginning.
  • To learn more about what the Verstandig Pavilion provides, please visit https://www.medstarhealth.org/building-medical-excellence
    View original content to download multimedia: https://www.prnewswire.com/news-releases/now-open-the-verstandig-pavilio...

Newly Unveiled Verstandig Pavilion at MedStar Georgetown University Hospital Promises Continued World-Class Care in a World-Class Facility

Retrieved on: 
Friday, December 1, 2023
Medicine, Foot, Hope, Nursing, Pavilion, Surgeon, Patient, Multimedia, MedStar Georgetown University Hospital, Health, CBS, MedSTAR, IMRIS, Neurosurgery, Perioperative, MedStar Health, Physician, Emergency department, Operating, Hospital, Medical imaging, MD

WASHINGTON, Nov. 30, 2023 /PRNewswire/ -- MedStar Georgetown University Hospital has officially unveiled the brand new Verstandig Pavilion, which is set to open December 10, 2023. A ribbon cutting ceremony featuring MedStar Health senior leaders, Philanthropist Grant Verstandig, community stakeholders, hospital associates, and CBS Evening News Anchor Norah O'Donnell — the event's emcee — celebrated the hospital's new 477-thousand sq. ft. addition which is set to become the D.C. region's most advanced healthcare facility.

Key Points: 
  • The highly anticipated opening will make MedStar Georgetown home to the Washington, D.C., region's most advanced healthcare facility.
  • WASHINGTON, Nov. 30, 2023 /PRNewswire/ -- MedStar Georgetown University Hospital has officially unveiled the brand new Verstandig Pavilion, which is set to open December 10, 2023.
  • "This is truly a transformational project, creating a world-class facility to match the world-class care provided by our physicians, nurses and associates.
  • "The Verstandig Pavilion will help MedStar Georgetown usher in a new era of healthcare in the region as we continue to serve the health care needs for decades to come."

PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors

Retrieved on: 
Tuesday, November 7, 2023
M.B.A, Perioperative, International, Kellogg-HKUST Executive MBA Program, Christianity in Singapore, Sheba Medical Center, Tel Aviv University, Polypide, R, Business administration, Partnership, Internal medicine, Medical device, Management, Sanofi

“We are thrilled to welcome Dr. Tweezer-Zaks to the PolyPid Board.

Key Points: 
  • “We are thrilled to welcome Dr. Tweezer-Zaks to the PolyPid Board.
  • She has had a distinguished career as a practicing physician, biopharmaceutical industry executive and sector investor,” said Jacob Harel, PolyPid’s Chairman.
  • I would also like to thank Anat for her distinguished service and counsel as a member of PolyPid’s Board since April 2008.
  • In her most recent role at Sanofi, she served as Global Established Products Medical Lead – Strategic Decision for Portfolio Enhancement.

Viseon Inc. Announces Strategic Market Expansion with 4K Advanced Digital Visualization Enabling Technology

Retrieved on: 
Tuesday, October 10, 2023
Surgery, Health, Medical Devices, Teaching, Minimally invasive spine surgery, ASC, Enabling technology, Endoscopy, Viseon Bus, Inc., Safety, Resident, Arriscope (surgical microscope), Artificial intelligence, Augmented reality, Education, Patient safety, CT, Perioperative, Surgeon, MRI, Digital Visual Interface, Machine learning, Medical imaging

Viseon Inc. announces the company is expanding their addressable market beyond minimally invasive spine surgery to focus on several additional market segments where both open and minimally invasive surgery can benefit clinically as well as economically from the Viseon technology, including enabling procedure transition to outpatient surgery centers.

Key Points: 
  • Viseon Inc. announces the company is expanding their addressable market beyond minimally invasive spine surgery to focus on several additional market segments where both open and minimally invasive surgery can benefit clinically as well as economically from the Viseon technology, including enabling procedure transition to outpatient surgery centers.
  • Viseon offers the first and only single-use disposable state-of-the-art 4K visualization system as an alternative to large capital-intense Surgical Microscopes, Endoscopes and Exoscopes.
  • Viseon’s Chief Executive Officer, Jeffrey Valko, commented, “After initially cutting our teeth in Minimally Invasive Spine Surgery, we are now expanding the clinical applications for our Enabling Technology, a 4K Advanced Digital Visualization (4K-ADV) Company, with clinical and economic utility across several surgical areas of opportunity.
  • About Viseon Inc.: Viseon Inc. is privately owned with a founding goal to advance open and minimally invasive surgery with innovative technology that enhances intraoperative visualization in an otherwise compromised setting with state of the art, single use 4K imaging technology.

Mindray Exhibiting at ANESTHESIOLOGY® Annual Meeting - Booth 1026

Retrieved on: 
Tuesday, October 10, 2023
Annual general meeting, Assembly, Perioperative, Health, FASA, Environment, Operating room management, Edwards, TE, Anesthesia, Moscone Center, SR, Nursing, Medical imaging, MD

MAHWAH, N.J., Oct. 10, 2023 /PRNewswire-PRWeb/ -- Mindray, a global developer of healthcare technologies and solutions for ultrasound, patient monitoring, and anesthesia, announced today that they are exhibiting at the 2023 ANESTHESIOLOGY® Annual Meeting at Moscone Center in San Francisco, CA, October 14-16. They will highlight their latest advancements in perioperative care, including a new collaboration with Edwards Lifesciences that can enable every high-acuity bed to have advanced hemodynamic monitoring to elevate patient care and clinical insights. All ANESTHESIOLOGY® attendees are invited to visit Booth 1026 to learn more about Mindray's innovative perioperative solutions.

Key Points: 
  • All ANESTHESIOLOGY® attendees are invited to visit Booth 1026 to learn more about Mindray's innovative perioperative solutions.
  • Rosen continued, "We are excited to showcase our complete perioperative solutions at ANESTHESIOLOGY® Annual Meeting and invite all attendees to stop by Booth 1026 in Moscone Center South and witness how we advance medical technologies to make healthcare more accessible."
  • Mindray will also host Dr. Richard Teames and Basem J Abdelmalak, MD, FASA, SAMBA-F, on Saturday and Sunday in Booth 1026 for educational sessions.
  • Through years of innovation, Mindray offers a comprehensive portfolio of leading-edge solutions to meet the diverse demands of evolving patient populations.

Genesis MedTech introduces China's first domestic brand of NPMA-approved antibacterial sutures

Retrieved on: 
Tuesday, September 12, 2023
Triclosan, Suture, Staphylococcus, Staphylococcus epidermidis, Infection, MRSA, Gram-negative bacteria, Hospital-acquired infection, Staphylococcus aureus, CDC, MRSE, Patient, Risk, Korea Disease Control and Prevention Agency, Perioperative, National Medical Products Administration, Growth, Methicillin-resistant Staphylococcus aureus, WHO, JAMA Surgery, Lancet, NMPA, Genesis, Dis, World Health Organization, Pharmaceutical industry, Vaccine

The newly developed antibacterial sutures are coated with triclosan, a broad-spectrum antimicrobial agent with activity against gram-positive and gram-negative bacteria.

Key Points: 
  • The newly developed antibacterial sutures are coated with triclosan, a broad-spectrum antimicrobial agent with activity against gram-positive and gram-negative bacteria.
  • Alongside the highly anticipated absorbable antibacterial sutures, Genesis MedTech continues to expand its suture product lines with comprehensive offerings.
  • Furthermore, its barbed absorbable sutures with black needle, non-absorbable surgical polypropylene sutures, and controlled-release needle sutures have been widely used in thousands of hospitals nationwide.
  • Warren Wang, Chairman and CEO of Genesis MedTech Group, expressed his excitement stating, "We are thrilled to achieve this significant milestone as the first domestic brand in China to develop antibacterial sutures.

New AAMI Standard on Water Quality for Medical Device Processing

Retrieved on: 
Wednesday, August 16, 2023
Medical device, Association of periOperative Registered Nurses, AAMI, Water quality, Water, USB On-The-Go, ANSI, Sterilization, Organization, Perioperative, Association for the Advancement of Medical Instrumentation, AORN, PH, Nursing

The first standard of its kind, ANSI/AAMI ST108:2023, Water for the processing of medical devices, revises and replaces AAMI TIR34:2014/(R)2021 , which provided information and guidance on water quality for device reprocessing.

Key Points: 
  • The first standard of its kind, ANSI/AAMI ST108:2023, Water for the processing of medical devices, revises and replaces AAMI TIR34:2014/(R)2021 , which provided information and guidance on water quality for device reprocessing.
  • AAMI’s Water Quality for Medical Device Processing Working Group developed ANSI/AAMI ST108 by reaching a consensus on research-based evidence and industry best practices.
  • Terra Kremer , co-chair of AAMI’s Water Quality for Medical Device Processing Working Group said:
    The release of this document will be a huge shift for the healthcare industry.
  • The current document AAMI TIR34 makes recommendations, but elevating its content to a standard will encourage healthcare facilities to voluntarily conform with best practices for device processing water quality.